Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amphastar is a biopharmaceutical company focused on complex generic and proprietary injectable, inhalation, and intranasal products and insulin API products, and its filings offer detailed insight into how this business is structured and governed.
Investors reviewing AMPH filings will find current reports on Form 8-K that describe material events such as license agreements, contract research agreements, manufacturing and distribution amendments, and related-party transactions with entities affiliated with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. These 8-Ks outline key terms for agreements covering proprietary peptides, AMP-110, recombinant peptide research cell banks for AMP-107, and regional distribution of BAQSIMI®.
Amphastar also files earnings-related 8-Ks that furnish press releases summarizing quarterly financial results, including net revenues, net income, and non-GAAP measures such as adjusted net income and adjusted diluted EPS. These disclosures explain how the company evaluates its operating performance and reconcile non-GAAP metrics to GAAP figures.
Through Stock Titan, users can monitor real-time updates from EDGAR as new Amphastar filings appear, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available. AI-powered summaries help explain the significance of complex agreements, highlight changes in licensing and manufacturing arrangements, and surface important details about pipeline assets, manufacturing footprint, distribution partnerships, and governance matters. The filings page also makes it easier to track board and management changes, share repurchase authorizations, and other corporate actions that Amphastar reports to the SEC.
Amphastar Pharmaceuticals, Inc. reports its full-year 2025 results and outlines an expanded injectable, inhalation, and intranasal drug portfolio. Net revenues were $719.9 million in 2025 compared with $732.0 million in 2024, while net income declined to $98.1 million from $159.5 million.
The company’s largest products include BAQSIMI glucagon nasal powder, Primatene MIST, glucagon, epinephrine, and lidocaine. Amphastar completed the global transition of BAQSIMI distribution, launched FDA‑approved albuterol and iron sucrose products in 2024–2025, and gained approvals for teriparatide and Ipratropium Bromide HFA.
Amphastar is investing heavily in complex generics, biosimilar insulins and proprietary peptides, backed by 163 R&D employees and vertically integrated API facilities in the U.S., France, and China. At February 20, 2026, the company had 45,370,171 common shares outstanding, and key U.S. wholesalers McKesson, Cencora and Cardinal Health together represented most of its net revenues.
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2025 results showing modestly lower sales but a sharp drop in profit. Full-year net revenues were $719,887,000 versus $731,967,000 a year earlier, while GAAP net income declined to $98,094,000 from $159,519,000, and GAAP diluted EPS fell to $2.03 from $3.06.
Adjusted non-GAAP net income decreased to $156,618,000 from $200,806,000, with adjusted diluted EPS of $3.25 compared with $3.86. BAQSIMI® was a key growth driver, with 2025 product revenues of $185,358,000 up from $126,898,000, while glucagon and epinephrine products declined. Operating expenses rose, particularly general and administrative and research and development.
The company generated cash flow from operating activities of $156,100,000 for 2025 and ended the year with cash, cash equivalents, and short-term investments totaling $282,812,000. Amphastar highlighted recent FDA approvals for iron sucrose and teriparatide injections and expanded its proprietary pipeline with three novel peptides and a fully synthetic corticotropin compound targeting oncology, ophthalmology, and immunology markets.
Amphastar Pharmaceuticals entered an exclusive license with Nanjing Hanxin to develop and sell a corticotropin product in the United States and Canada. Amphastar paid an upfront $2 million and may owe up to $14 million in development milestones, up to $75 million in sales milestones, and annual royalties capped at $7.5 million with a lifetime cap of $60 million for this product. Hanxin will pay Amphastar royalties on sales of licensed products that use Amphastar patents or regulatory exclusivity outside this territory.
The license term runs at least ten years from first commercial sale in each region, with an option for Amphastar to extend. Amphastar and Hanxin also expanded their existing distribution and manufacturing agreements to cover additional regions and products, which the company does not consider material to its financial condition or results. These agreements are related-party transactions because Amphastar’s founders and their family beneficially own a majority of Hanxin; the company states its audit committee evaluated and approved the new arrangements.
Amphastar Pharmaceuticals' senior executive reports option exercise and share sale. The Senior EVP, Production Center exercised an employee stock option to acquire 9,787 shares of Amphastar Pharmaceuticals common stock at an exercise price of $11.33 per share on 12/17/2025. On the same day, 9,787 common shares were sold at a weighted average price of $26.1959 per share, with individual sale prices ranging from $25.97 to $26.50.
After these transactions, the reporting person directly owns 138,043 common shares. In addition, 99,668 shares are held by the Zhou Family Trust, for which the reporting person serves as trustee, and 5,000 shares are held by the reporting person’s spouse. The option shares were fully vested and immediately exercisable at the time of exercise.
Amphastar Pharmaceuticals reported that one of its directors sold Amphastar common stock in two open-market transactions. On December 11, 2025, the director sold 1,737 shares at $25.688 per share. On December 12, 2025, the director sold 2,426 shares at a weighted average price of $25.9226 per share, with individual trades ranging from $25.9225 to $25.945.
After these sales, the director beneficially owned 71,368 shares of Amphastar common stock, held directly. The report states that full detail on the number of shares sold at each separate price is available upon request from the issuer, any security holder, or the SEC staff.
Amphastar Pharmaceuticals director reports option exercise and share sale. A director of Amphastar Pharmaceuticals, Inc. (AMPH) exercised a stock option for 4,179 shares of common stock on 11/25/2025 at an exercise price of $16.69 per share. On the same date, the director sold 4,179 shares of common stock in an open-market transaction at a weighted average price of $27.1006 per share, with individual sale prices ranging from $27.10 to $27.125. After these transactions, the director beneficially owns 35,183 shares of Amphastar common stock held directly. The option exercised covered fully vested, immediately exercisable shares and now has a remaining balance of zero derivative securities.
Amphastar Pharmaceuticals, Inc. (AMPH) reported an insider transaction by a director involving company common stock. On 11/13/2025, the director exercised a stock option for 16,679 shares of common stock at an exercise price of $16.69 per share and acquired those shares. On the same date, the director sold 16,679 shares of common stock at a weighted average price of $26.4906 per share, with individual sale prices ranging from $26.43 to $26.57. After these transactions, the director beneficially owned 75,531 shares of Amphastar common stock directly. The stock option covering 16,679 shares, which was fully vested and immediately exercisable and had an expiration date of 06/07/2026, now shows 0 derivative securities remaining beneficially owned.
Amphastar Pharmaceuticals reported Q3 2025 results. Net revenues were $191,840 thousand, with gross profit of $98,646 thousand and income from operations of $25,320 thousand. Net income was $17,350 thousand, or diluted EPS of $0.37.
Year to date, net revenues totaled $536,782 thousand and net income was $73,665 thousand. Q3 product mix included BAQSIMI at $53,608 thousand, Primatene MIST at $28,808 thousand, Lidocaine at $12,932 thousand, Epinephrine at $18,789 thousand, Glucagon at $13,558 thousand, and other products at $64,145 thousand.
Cash and cash equivalents were $216,265 thousand, short‑term investments $59,944 thousand, and inventories $185,932 thousand as of September 30, 2025. Total assets were $1,666,222 thousand. Long‑term debt (including the 2.00% 2029 convertible notes and a term loan) totaled $619,798 thousand, with long‑term debt, net of issuance costs and current portion, at $608,582 thousand. Operating cash flow for the nine months was $123,252 thousand. The company repurchased $55,070 thousand of shares year to date; treasury stock stood at $(387,653) thousand. Common shares outstanding were 45,952,174 as of October 31, 2025.
Amphastar Pharmaceuticals filed an 8-K stating it issued a press release announcing financial results for the three months ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
Amphastar Pharmaceuticals (AMPH): director sale reported. On 11/03/2025, a director sold 500 shares of common stock at a weighted average price of $25.2662 under a Rule 10b5-1 trading plan adopted on November 26, 2024. The trades occurred at prices ranging from $25.00 to $25.47. After this transaction, the reporting person beneficially owns 75,531 shares, held directly.